

EQUITY INSIGHTS

Mediclinic International: Facing Regulatory Headwinds

Issue date: 31 January 2019

THE BUSINESS PAST AND PRESENT

Mediclinic ran a successful South African (32% of group revenue) and Swiss (45% of revenue) business in favorable environments for much of the past decade. High margins and strong cash generation were earned and the business re-invested most of that cash into growth and de-gearing post the FY'08 Hirslanden (Switzerland) acquisition.

Over the past few years, the group changed substantially, through the acquisition of Spire Healthcare in 2015, the merger with Al Noor in 2016 and acquisitions of additional Swiss hospitals, with notably more shares in issue today. Although the South African business continues to operate soundly, material operating and regulatory challenges were encountered in the Swiss, UAE and UK businesses.

BUSINESS CHALLENGES

- Growth through share issuances and the Al Noor merger, has not translated into a per share benefit for shareholders in recent years.
- Approximately CHF 1 billion worth of impairments collectively from the Swiss, UAE and UK regions reported in FY'18 and FY'19.
- Swiss regulations have been introduced to structurally reduce healthcare costs. These include outpatient tariff reductions and a decline in supplementary insurance and hospital stays through pushing various procedures from 'inpatient' to 'outpatient'.
- The net result has been sharply reduced profitability, even prior to the regulations being fully implemented in CY'19.

BUSINESS MODEL ADJUSTMENT

In response to the regulatory changes, the group is having to shift its Swiss business model away from highly profitable inpatient supplementary-insured clients, toward outpatient and basic-insured inpatient clients where profitability is not yet proven on aggregate. Revenue per bed and per patient is declining.

It has proven challenging to reduce the cost base of the Swiss business which includes medical staff, occupancy costs and debt servicing. Ongoing equipment investment and the associated depreciation costs are essential to maintain a high-end brand and attract the best doctors who in turn bring in the high-margin business. Operating activity is increasing amidst revenue pressure as the business grows low-margin outpatients and keeps beds occupied with less profitable basic-insured inpatients. Overall, operating margins are in decline.




Changes in regulation in the healthcare sector can substantially alter future cash flow expectations and the value of a business. Mediclinic has experienced this in Abu Dhabi with Al Noor and now in Switzerland. The potential for wide ranging reforms in South Africa to reduce the cost of healthcare also exists. The unstable regulatory environments in which the group operates has increased its risk profile.

CONCLUSION

Future prospects for the Swiss business and therefore for the group are now less clear as Mediclinic adapts to its changing environment. Risk is elevated at present with lower expected cash flow amidst high gearing in Switzerland, and ongoing regulatory headwinds.

| | Mediclinic International |
|---------------------|--------------------------|
| Market Cap | R 40bn |
| Current Share Price | R 54.25 |
| 52w High-Low Range | R 52 - R 120.2 |
| Forward PE | 10.5x |
| Forward DY | 2.6% |
| Financial Year End | 31 March 2018 |

Sources: FactSet, January 2019



FOR MORE INFORMATION PLEASE CONTACT:



JP DU PLESSIS

Director – Equity Management

t: +27 21 446 2106

e: jp.duplessis@stonehagefleming.com



JEREMY GORVEN, CFA

Senior Analyst – Equity Management

t: +27 21 446 2172

e: jeremy.gorven@stonehagefleming.com



RYAN DE KOCK, CFA

Analyst – Equity Management

t: +27 21 446 2112

e: ryan.dekock@stonehagefleming.com

Stonehage Fleming Investment Management (South Africa) (Pty) Ltd,
First Floor, North Block, Waterway House
3 Dock Road, Victoria & Alfred Waterfront
Cape Town 8001 South Africa
t: +27 21 446 2100
e: enquiries@stonehagefleming.com
stonehagefleming.com

Jeremy Gorven and Ryan de Kock are representatives under FAIS supervision

This document is intended to provide only general information and to highlight points of interest. It is not intended to be comprehensive or sufficient for making decisions and should not be relied upon. Specific financial and taxation advice should be sought on the facts of any matter before action is taken. This document is not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) it is prohibited.

Where investments are involved, nothing in this documents should be taken as expressed or implied indication, representation warranty or guarantee of performance whether in respect of income or capital growth. No warranty or representation is given as to the accuracy or completeness of this document and no liability is accepted for any errors or omissions that the document may contain. The value of investments and any income derived can go down as well as up. Investors may not get back the full amount invested. Past performance is not a reliable indicator of future results. Where an investment is denominated in a currency other than the currency where the investor is resident, investment returns may increase or decrease as a result of currency fluctuations.

Stonehage Fleming Investment Management (South Africa) (Pty) Ltd, other affiliated companies of the Stonehage Group and directors and employees of these companies may from time to time have a long or short positions in the securities mentioned in this document and may add to or dispose of such securities.

This document is issued and approved for distribution in South Africa by Stonehage Fleming Investment Management (South Africa) (Pty) Ltd, which is an authorised Financial Services Provider (FSP No. 42847).